J&J Describes Eprex Safety Findings In Petition Against Follow-On Biologics
Executive Summary
Johnson & Johnson believes that safety issues triggered by a change in stabilizers used in production of the erythropoietin Eprex support the biotechnology industry's position that "follow-on" biologics need separate clinical trials
You may also be interested in...
Thinking About Biosimilars? Meet Regulators First, Then Plan Global Development – BioAsia Conference
Opportunities in biosimilars are aplenty but regulators advise a cautious development plan to avoid late failures arising out of non-compliance.
FDA Biologic Manufacturing Comparability Policy May Apply To Follow-Ons
FDA's comparability guidance for biologics undergoing manufacturing process changes could be used to establish standards for the approval of generic biologics, according to former agency reviewers
FDA Biologic Manufacturing Comparability Policy May Apply To Follow-Ons
FDA's comparability guidance for biologics undergoing manufacturing process changes could be used to establish standards for the approval of generic biologics, according to former agency reviewers